190 related articles for article (PubMed ID: 33531379)
1. Paraneoplastic Cerebellar Degeneration: The Importance of Including CDR2L as a Diagnostic Marker.
Herdlevær I; Haugen M; Mazengia K; Totland C; Vedeler C
Neurol Neuroimmunol Neuroinflamm; 2021 Mar; 8(2):. PubMed ID: 33531379
[TBL] [Abstract][Full Text] [Related]
2. A cerebellar degeneration-related protein 2-like cell-based assay for anti-Yo detection in patients with paraneoplastic cerebellar degeneration.
Erikstad KI; Herdlevaer I; Peter E; Haugen M; Totland C; Vedeler C
Eur J Neurol; 2023 Jun; 30(6):1727-1733. PubMed ID: 36912432
[TBL] [Abstract][Full Text] [Related]
3. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
4. Cerebellar degeneration-related proteins 2 and 2-like are present in ovarian cancer in patients with and without Yo antibodies.
Raspotnig M; Haugen M; Thorsteinsdottir M; Stefansson I; Salvesen HB; Storstein A; Vedeler CA
Cancer Immunol Immunother; 2017 Nov; 66(11):1463-1471. PubMed ID: 28710511
[TBL] [Abstract][Full Text] [Related]
5. CDR2 and CDR2L line blot performance in PCA-1/anti-Yo paraneoplastic autoimmunity.
Vorasoot N; Scharf M; Miske R; Thakolwiboon S; Dubey D; Mills JR; Pittock SJ; Zekeridou A; Ott A; McKeon A
Front Immunol; 2023; 14():1265797. PubMed ID: 37841252
[TBL] [Abstract][Full Text] [Related]
6. CDR2L Is the Major Yo Antibody Target in Paraneoplastic Cerebellar Degeneration.
Kråkenes T; Herdlevaer I; Raspotnig M; Haugen M; Schubert M; Vedeler CA
Ann Neurol; 2019 Aug; 86(2):316-321. PubMed ID: 31148214
[TBL] [Abstract][Full Text] [Related]
7. Localization of CDR2L and CDR2 in paraneoplastic cerebellar degeneration.
Herdlevaer I; Kråkenes T; Schubert M; Vedeler CA
Ann Clin Transl Neurol; 2020 Nov; 7(11):2231-2242. PubMed ID: 33009713
[TBL] [Abstract][Full Text] [Related]
8. Paraneoplastic cerebellar degeneration: Yo antibody alters mitochondrial calcium buffering capacity.
Panja D; Vedeler CA; Schubert M
Neuropathol Appl Neurobiol; 2019 Feb; 45(2):141-156. PubMed ID: 29679372
[TBL] [Abstract][Full Text] [Related]
9. Expression of cerebellar degeneration-related proteins CDR2 and CDR2L in human and rat brain tissue.
Raspotnig M; Kråkenes T; Herdlevær I; Haugen M; Vedeler C
J Neuroimmunol; 2022 Jan; 362():577766. PubMed ID: 34823119
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes.
Déchelotte B; Muñiz-Castrillo S; Joubert B; Vogrig A; Picard G; Rogemond V; Pinto AL; Lombard C; Desestret V; Fabien N; Honnorat J
Neurol Neuroimmunol Neuroinflamm; 2020 May; 7(3):. PubMed ID: 32170044
[TBL] [Abstract][Full Text] [Related]
11. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
[TBL] [Abstract][Full Text] [Related]
12. Anti-Yo positive paraneoplastic cerebellar degeneration associated with ovarian carcinoma: case report and review of the literature.
Cao Y; Abbas J; Wu X; Dooley J; van Amburg AL
Gynecol Oncol; 1999 Oct; 75(1):178-83. PubMed ID: 10502450
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic CDR2 and CDR2L antibodies affect Purkinje cell calcium homeostasis.
Schubert M; Panja D; Haugen M; Bramham CR; Vedeler CA
Acta Neuropathol; 2014 Dec; 128(6):835-52. PubMed ID: 25341622
[TBL] [Abstract][Full Text] [Related]
14. Human epidermal growth factor receptor 2 overexpression in breast cancer of patients with anti-Yo--associated paraneoplastic cerebellar degeneration.
Rojas-Marcos I; Picard G; Chinchón D; Gelpi E; Psimaras D; Giometto B; Delattre JY; Honnorat J; Graus F
Neuro Oncol; 2012 Apr; 14(4):506-10. PubMed ID: 22351748
[TBL] [Abstract][Full Text] [Related]
15. Paraneoplastic cerebellar degeneration associated with an onconeural antibody against creatine kinase, brain-type.
Tetsuka S; Tominaga K; Ohta E; Kuroiwa K; Sakashita E; Kasashima K; Hamamoto T; Namekawa M; Morita M; Natsui S; Morita T; Tanaka K; Takiyama Y; Nakano I; Endo H
J Neurol Sci; 2013 Dec; 335(1-2):48-57. PubMed ID: 24018129
[TBL] [Abstract][Full Text] [Related]
16. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
17. Case Report: A False Negative Case of Anti-Yo Paraneoplastic Myelopathy.
Bartley CM; Parikshak NN; Ngo TT; Alexander JA; Zorn KC; Alvarenga BA; Kang MK; Pedriali M; Pleasure SJ; Wilson MR
Front Neurol; 2021; 12():728700. PubMed ID: 34744969
[TBL] [Abstract][Full Text] [Related]
18. Paraneoplastic cerebellar degeneration with anti-Yo antibodies associated with metastatic uveal melanoma.
Valpione S; Zoccarato M; Parrozzani R; Pigozzo J; Giometto B; Laveder F; Aliberti C; Chiarion-Sileni V
J Neurol Sci; 2013 Dec; 335(1-2):210-2. PubMed ID: 24035275
[TBL] [Abstract][Full Text] [Related]
19. Cytotoxic T cells against a peptide of Yo protein in patients with paraneoplastic cerebellar degeneration and anti-Yo antibody.
Tanaka M; Tanaka K; Tokiguchi S; Shinozawa K; Tsuji S
J Neurol Sci; 1999 Sep; 168(1):28-31. PubMed ID: 10500270
[TBL] [Abstract][Full Text] [Related]
20. Immune and Genetic Signatures of Breast Carcinomas Triggering Anti-Yo-Associated Paraneoplastic Cerebellar Degeneration.
Peter E; Treilleux I; Wucher V; Jougla E; Vogrig A; Pissaloux D; Paindavoine S; Berthet J; Picard G; Rogemond V; Villard M; Vincent C; Tonon L; Viari A; Honnorat J; Dubois B; Desestret V
Neurol Neuroimmunol Neuroinflamm; 2022 Sep; 9(5):. PubMed ID: 35821104
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
